These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11909981)

  • 41. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levodopa strengths and weaknesses.
    Jankovic J
    Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease.
    Das B; Kandegedara A; Xu L; Antonio T; Stemmler T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2017 Apr; 8(4):723-730. PubMed ID: 28106982
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
    Friedman A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term studies of dopamine agonists.
    Hubble JP
    Neurology; 2002 Feb; 58(4 Suppl 1):S42-50. PubMed ID: 11909984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
    Tulloch IF
    Neurology; 1997 Jul; 49(1 Suppl 1):S58-62. PubMed ID: 9222275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dopamine agonist-based strategies in the treatment of Parkinson's disease.
    Antonini A; Barone P
    Neurol Sci; 2008 Dec; 29 Suppl 5():S371-4. PubMed ID: 19381765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies.
    Herrero MT; Pagonabarraga J; Linazasoro G
    Neurologist; 2011 Nov; 17(6 Suppl 1):S54-66. PubMed ID: 22045327
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
    Kuzel MD
    Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease.
    Takahashi-Niki K; Inafune A; Michitani N; Hatakeyama Y; Suzuki K; Sasaki M; Kitamura Y; Niki T; Iguchi-Ariga SM; Ariga H
    J Pharmacol Sci; 2015 Mar; 127(3):305-10. PubMed ID: 25837927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targets for neuroprotection in Parkinson's disease.
    Yacoubian TA; Standaert DG
    Biochim Biophys Acta; 2009 Jul; 1792(7):676-87. PubMed ID: 18930814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine receptor agonists for protection and repair in Parkinson's disease.
    Ferrari-Toninelli G; Bonini SA; Cenini G; Maccarinelli G; Grilli M; Uberti D; Memo M
    Curr Top Med Chem; 2008; 8(12):1089-99. PubMed ID: 18691134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroprotection in PD--a role for dopamine agonists?
    Schapira AH
    Neurology; 2003 Sep; 61(6 Suppl 3):S34-42. PubMed ID: 14504378
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.